BioCentury | Aug 3, 2018
Clinical News

Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection

...of emtricitabine plus tenofovir disoproxil fumarate or abacavir plus lamivudine. Viral suppression was defined as HIV RNA...
...patients with HIV-1 RNA levels of <50 copies/mL at week 48; proportion of patients with HIV RNA...
BioCentury | Apr 18, 2018
Preclinical News

Study challenges FCGR2A as latent HIV marker

...HIV patients and lymph node cells from both viremic and ART-suppressed patients co-expressed FCGR2A and HIV RNA...
BioCentury | Feb 14, 2018
Distillery Therapeutics

Infectious disease

...spleen. In another humanized mouse model of HIV infection, the prodrug decreased levels of the HIV RNA...
BioCentury | May 30, 2017
Clinical News

Gilead’s HIV combo non-inferior in four Phase III trials

...the bictegravir combo was non-inferior on the primary endpoint of the proportion of patients with HIV RNA...
BioCentury | Nov 17, 2014
Clinical News

Doravirine: Additional Phase IIb data

...transcriptase inhibitor (NNRTI) Indication: Treat HIV infection in treatment-naive patients Endpoint: Proportion of patients with HIV RNA...
...proportion of patients with a CNS event at week 8; proportion of patients with plasma HIV RNA...
BioCentury | Sep 29, 2014
Clinical News

Tenofovir alafenamide fumarate: Phase III data

...the primary endpoint of non-inferiority to Gilead's Stribild elvitegravir/cobicistat/emtricitabine/tenofovir in the proportion of patients with HIV RNA...
BioCentury | Sep 29, 2014
Clinical News

Tenofovir alafenamide fumarate: Phase III data

...the primary endpoint of non-inferiority to Gilead's Stribild elvitegravir/cobicistat/emtricitabine/tenofovir in the proportion of patients with HIV RNA...
BioCentury | Sep 25, 2014
Clinical News

Gilead's TAF-based regimen meets Phase III endpoint

...Study 104, 93.1% of patients receiving a once-daily single-tablet regimen of TAF plus elvitegravir/cobicistat/emtricitabine achieved HIV RNA...
BioCentury | Jul 23, 2014
Clinical News

Celgene cancer drug reactivates latent HIV reservoirs

...evaluating vorinostat from Merck & Co. Inc. (NYSE:MRK) in a Phase I/II trial to compare HIV RNA...
BioCentury | Mar 10, 2014
Finance

Highlights of weekly biotech stock moves

...treat HIV. In a Phase I trial, one patient who received the cell therapy had HIV RNA...
Items per page:
1 - 10 of 317